Results 221 to 230 of about 108,143 (259)
New England Journal of Medicine, 2021 Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of all lymphomas.
Laurie H Sehn, Gilles Salles
exaly +6 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Critical Reviews in Oncology/Hematology, 2013
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults accounting for 31% of all NHL in Western Countries. Following, morphological, biological and clinical studies have allowed the subdivision of DLBCLs into morphological variants, molecular and immunophenotypic subgroups and distinct disease entities.
MARTELLI, Maurizio +5 more
openaire +2 more sources
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults accounting for 31% of all NHL in Western Countries. Following, morphological, biological and clinical studies have allowed the subdivision of DLBCLs into morphological variants, molecular and immunophenotypic subgroups and distinct disease entities.
MARTELLI, Maurizio +5 more
openaire +2 more sources
Pathology, 2018
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma worldwide, representing approximately 30-40% of all cases in different geographic regions. Patients most often present with a rapidly growing tumour mass in single or multiple, nodal or extranodal sites.
Shaoying, Li +2 more
openaire +2 more sources
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma worldwide, representing approximately 30-40% of all cases in different geographic regions. Patients most often present with a rapidly growing tumour mass in single or multiple, nodal or extranodal sites.
Shaoying, Li +2 more
openaire +2 more sources
Everolimus in Diffuse Large B-Cell Lymphomas
Future Oncology, 2015Satisfactory treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is not currently available and novel therapies are needed. mTOR is an intracellular kinase that is part of an aberrantly activated pathway in DLBCL. Preclinical studies in DLBCL cell lines demonstrated that everolimus, an oral selective mTOR inhibitor, induces cell ...
Merli, Michele +4 more
openaire +4 more sources
Diffuse Large B-Cell Lymphomas and Burkitt Lymphoma
Hematology/Oncology Clinics of North America, 2009Diffuse large B-cell lymphomas (DLBCLs) and Burkitt lymphoma (BL) account for the majority of aggressive lymphomas in adults and children. DLBCLs exhibit marked biological heterogeneity and variable clinical presentation and clinical course. Conversely, BL is genetically relatively homogeneous but associated with variable clinicopathological features ...
Laurence, de Leval +1 more
openaire +2 more sources
Seminars in Radiation Oncology, 2007
Diffuse large B-cell lymphoma (DLBCL) is one of the most common subtypes of non-Hodgkin lymphoma. It is a heterogeneous disease, and a distinctive subgroup of patients with different treatment outcome can be identified based on clinical and molecular prognostic factors.
openaire +2 more sources
Diffuse large B-cell lymphoma (DLBCL) is one of the most common subtypes of non-Hodgkin lymphoma. It is a heterogeneous disease, and a distinctive subgroup of patients with different treatment outcome can be identified based on clinical and molecular prognostic factors.
openaire +2 more sources
NHL (diffuse large B-cell lymphoma).
BMJ clinical evidence, 2016Non-Hodgkin's lymphoma (NHL) is the sixth most common cancer in the UK; 9443 new cases were diagnosed in the UK in 2002, and it caused 4418 UK deaths in 2003. Incidence rates show distinct geographical variation, with age-standardised incidence rates ranging from 17 per 100,000 in northern America to 4 per 100,000 in south-central Asia. NHL occurs more
Fiona, Kyle, Mark, Hill
openaire +3 more sources
Diffuse large B-cell lymphoma in the older
Critical Reviews in Oncology/Hematology, 2011The incidence of diffuse large B-cell lymphoma (DLCL) in the older is growing to the point of becoming a health priority in the next decades. Prognostic factors and the biology of the tumor are not very different between younger and older populations.
A, Gutiérrez +3 more
openaire +2 more sources
Treatment of diffuse large B-cell lymphomas
memo - Magazine of European Medical Oncology, 2009Diffuse large B-cell lymphoma represent 40% of all lymphoma. The development of dose-dense chemotherapeutic regimens and the application of the monoclonal CD20 antibody rituximab improve the prognosis significantly. Evaluation of clinical risk factors (age, stage, LDH, ECOG performance status, number of extranodal involvement) at initial diagnosis are ...
B, Gleissner, C, Zwick, M, Pfreundschuh
openaire +2 more sources